For more than 19 years, Texcell has been providing comprehensive, standard protocols for evaluating your cell banks, raw materials and cell derivatives such as monoclonal antibodies, recombinant proteins, vaccines and gene therapy products.
Each protocol is drawn up in accordance with the EU or US Pharmacopoeia and EMEA or FDA guidelines. To verify assay accuracy and reproducibility during development, each test has followed a specific development process (set out in a validation file). Each protocol is designed to GLP standards, and if you request GMP-standard assays for batch release testing, we will adapt our SOP to suit your needs.
To guarantee the biosafety of your product, this section provides you with an exhaustive list of the protocols we offer.
However, customised protocols are also available on request.
Moreover, at the end of the section, you will find several case studies with specific testing strategies, depending on the cell line used.
If you need to evaluate the biosafety of recombinant proteins, monoclonal antibodies, gene therapy vectors or cell lines, do not hesitate to contact us!
